CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0685 (clinicaltrials.gov NCT No: NCT00948064)
Title:A Phase 2 Trial of Vorinostat in Combination with Azacitidine in Patients with Newly-Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome who are ineligible for other Leukemia Protocols
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Azacitidine; Vorinostat
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
azacitidine and vorinostat can help to control AML or MDS better than
azacitidine alone. The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Azacitidine
Vorinostat
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Merck and Co.
Pharmion Corporation
Return Visit:Courses will be repeated every 3 to 8 weeks.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults